



CLAIMS

1. A compound of formula **PQ**:




2. A compound according to claim 1, of formula **P** or **Q**:




3. (1*S*,4*R*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine according to claim 1.
4. (1*R*,4*S*)-*N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine according to claim 1.
5. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to any of claims 1 to 4.
6. A tablet or capsule according to claim 5.

7. A method for treating CNS disorders in a human, the method comprising administering to a person in need of treatment for a CNS disorder, a therapeutically effective amount of:

- (a) (1*R*,4*S*)-*trans* 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine



- (b) (1*S*,4*R*)-*trans* 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine



- (c) a mixture of **P** and **Q**; or
 (d) a pharmaceutically acceptable salt thereof.

8. The method according to claim 7, wherein the CNS disorder is a mood disorder.


9. The method according to claim 8, wherein the mood disorder is depression.

10. The method according to claim 8, wherein the CNS disorder is an anxiety-related disorder.


11. The method according to claim 10, wherein the anxiety-related disorder is obsessive compulsive disorder.

12. The method according to claim 7, wherein the CNS disorder is a disruptive behavior disorder.
13. The method according to claim 12, wherein the disruptive behavior disorder is one of attention deficit disorder (ADD) or attention deficit / hyperactivity disorder (ADHD).
14. The method according to claim 7, wherein the CNS disorder is a sexual dysfunction.
15. The method according to claim 7, wherein the CNS disorder is a substance abuse disorder.
16. The method according to claim 7, wherein the CNS disorder is an eating disorder.
17. A method according to claim 7, wherein the CNS disorder is premenstrual syndrome disorder.
18. A method for the prophylaxis of migraine in a human, the method comprising administering to a person at risk or in need of therapy for a migraine, a therapeutically effective amount of a compound chosen from:

- (a) (1*R*,4*S*)-*trans* 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine




- (b) (1*S*,4*R*)-*trans* 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine




- (c) a mixture of **P** and **Q**; and
 (d) a pharmaceutically acceptable salt thereof.

19. A method for treating psychoses in a human, the method comprising administering to a person in need of treatment for a psychoses, a therapeutically effective amount of:

- (a) (1*R*,4*S*)-*trans* 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine



- (b) (1*S*,4*R*)-*trans* 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine




- (c) a mixture of **P** and **Q** ; or
 (d) a pharmaceutically acceptable salt thereof, together with

- (e) a therapeutically effective amount of a D₂ antagonist, or a pharmaceutically acceptable salt thereof.


20. The method according to claim 19, wherein the D₂ antagonist is olanzapine.

21. A method for treating psychoses in a human, the method comprising administering to a person in need of treatment for a psychoses, a therapeutically effective amount of:

- (a) (1*R*,4*S*)-*trans* 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine




- (b) (1*S*,4*R*)-*trans* 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine




- (c) a mixture of **P** and **Q** ; or
- (d) a pharmaceutically acceptable salt thereof, together with
- (e) a therapeutically effective amount of a typical antipsychotic agent, or a pharmaceutically acceptable salt thereof.

22. A method for treating psychoses in a human, the method comprising administering to a person in need of treatment for a psychoses, a therapeutically effective amount of:

- (a) (1*R*,4*S*)-*trans* 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine



- (b) (1*S*,4*R*)-*trans* 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine



- (c) a mixture of **P** and **Q** ; or
 (d) a pharmaceutically acceptable salt thereof, together with
 (e) a therapeutically effective amount of an atypical antipsychotic agent, or a pharmaceutically acceptable salt thereof.

23. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine, the method comprising:

- (a) reacting 4-(3,4-dichlorophenyl)-3,4-dihydro-1-naphthalenone with an excess of formic acid and formamide to provide *N*-[4-(3,4-dichloro phenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide; and
 (b) hydrolyzing the *N*-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro naphthalen-1-yl]formamide with aqueous acid, yielding 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine.